Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transdermal placebo Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 25, 2026, 12:19 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 12:19 AM EDT
Not listed Phase 1 Interventional

Nicotine Treatment of Mild Cognitive Impairment (MCI)

NCT00091468
View directory record Official record
Conditions
Age-Related Memory Disorders
Interventions
Transdermal nicotine patch, Placebo transdermal patch
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Durham, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Results available

Targeted Interventions for Weight-Concerned Smokers

NCT00105482
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Naltrexone, Transdermal nicotine replacement, Behavioral counseling
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Results available

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

NCT02314156
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Telapristone Acetate, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
West Hollywood, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Flushing Reduction Associated With Nitrates

NCT02714205
View directory record Official record
Conditions
Menopausal Hot Flashes
Interventions
transdermal nitroglycerin, Placebo
Drug
Lead sponsor
Alison Huang, MD
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 3 Interventional

HKT-500 in the Treatment of Adult Patients With Ankle Sprain

NCT00927641
View directory record Official record
Conditions
Ankle Sprain
Interventions
Ketoprofen Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

KEEPS Mammographic Density And Breast Health Ancillary Study

NCT02524561
View directory record Official record
Conditions
Mammographic Density, Abnormal Mammogram
Interventions
CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 25, 2026, 12:19 AM EDT
Terminated Phase 2 Interventional Results available

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

NCT02349386
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 25, 2026, 12:19 AM EDT
Terminated Not applicable Interventional

Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes

NCT00567528
View directory record Official record
Conditions
Soft Tissue Injury
Interventions
ibuprofen
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years to 19 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 25, 2026, 12:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery

NCT00790829
View directory record Official record
Conditions
Postoperative Pain
Interventions
transdermal nicotine patch
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

NCT03440112
View directory record Official record
Conditions
Parkinson Disease
Interventions
Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020)
Drug
Lead sponsor
Nicolaas Bohnen, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 25, 2026, 12:19 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 25, 2026, 12:19 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

NCT01426464
View directory record Official record
Conditions
Glaucoma
Interventions
0.005% Latanoprost dosed once.
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain

NCT00312195
View directory record Official record
Conditions
Chronic Non-malignant Pain
Interventions
Buprenorphine transdermal patch, Placebo to match BTDS
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
21
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Not applicable Interventional Results available

Enhancing a High School Based Smoking Cessation Program

NCT01145001
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Cognitive Behavioural Therapy, Contingency Management, Nicotine Transdermal Patch
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
14 Years to 19 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

NCT03614663
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel
Drug · Other
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Outcomes of Low Testosterone

NCT02758431
View directory record Official record
Conditions
Hypogonadism
Interventions
Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCT00218231
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder
Interventions
300 mg/day bupropion-sr, 0 mg/day bupropion-sr
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 12:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bioenergetic Effects of Aging and Menopause (BEAM)

NCT04043520
View directory record Official record
Conditions
Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions
GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 25, 2026, 12:19 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00338312
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 25, 2026, 12:19 AM EDT